Whole-Exome and Whole-Genome Sequencing of Candidate Pharmacogenomic and Schizophrenia-Related Genes in Sudanese Families with Schizophrenia Authors: Safa A Abdalla, Azza Saeed, Lamees Ahmed, Safa Abuswar, Mudathir Salih, Amel Eltigani, Iman H Abdoon, Bashier Osman, Muntaser E Ibrahim Published: 2026 ABSTRACT BackgroundSchizophrenia is considered a neuro-developmental disorder leading to disastrous lifelong disability of the patients and their families. There is a lack of data regarding pharmacogenomics of schizophrenia in Sudan. This study aimed to identify different genes affecting the treatment outcomes in Sudanese patients with schizophrenia.MethodsA case-control study was conducted on seven families having more than one member diagnosed with schizophrenia. This was a small exploratory family-based sequencing study involving 18 affected individuals and 8 controls from seven families. Ethical clearance and informed consent were obtained. Demographic data were collected using a standardized data collection sheet. DNA was extracted from blood samples collected from patients and control groups. Then, whole-exome and genome sequencing were performed. Sixty-six genes associated with schizophrenia, treatment, and treatment resistance were selected from the variant calling file. Variants showing single-nucleotide polymorphisms (SNPs) were identified. These variants were then classified based on their impact on the protein-coding sequence into high- and moderate-impact. Moreover, indel mutations were also identified.ResultsTwelve variants of seven genes (COMT, FMO1, LPL, CYP2E1, ABCC1, GRM3, CYP2C9) were identified as genes with impact and potential association with schizophrenia (p-value=0.006632). Forty-three genes had a moderate impact, and they showed a potential association with schizophrenia (p-value=0.0004436). Two variants were indel mutations (CYP2D6, DTNBP1) and showed association with schizophrenia (p-value=0.004741). The p-values were generated from different databases.ConclusionThis exploratory family-based sequencing study identified several potentially relevant pharmacogenomic and schizophrenia-associated variants in Sudanese families, warranting validation in larger and ethnically diverse cohorts. Introduction Schizophrenia is considered a severe brain disorder that produces a lifetime disability and emotional distress, which affects individuals.1 Symptoms of schizophrenia typically start to develop in late adolescence or early adulthood.2 Adult onset of schizophrenia occurs between 20 and 28 years in males and 28 and 32 years in females.3 The onset in children is rather rare, as is the case for middle or old age.4 The chronic course of schizophrenia fluctuates between positive symptoms like paranoid delusions and auditory hallucinations, accompanied by negative symptoms such as reduced emotions, speech, and interest. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)5 schizophrenia is characterized by five key symptoms: delusions, hallucinations, disorganized speech, catatonic behavior, and negative symptoms. A diagnosis requires the presence of two or more of these criteria for at least one month.6 Schizophrenia is a chronic and debilitating disorder that affects approximately 1% of the global population. Despite its low incidence, acute schizophrenia has the highest disability rate compared with other physical and mental disorders.7 In Sudan, in 2019, there were 78,423 prevalent cases of schizophrenia, with 6167 incident cases.8 Out of 7340 admissions in the five main psychiatric hospitals in Khartoum State during the period from 2011 to 2015, a total of 36 patients died while receiving treatment, and one-third of them were diagnosed with schizophrenia. The death rate was estimated to be 7.2 per year; two-thirds of the deceased patients were men.9 For a long period, schizophrenia was known as a disorder of unknown etiology. Currently, schizophrenia is recognized to be a multi-factorial syndrome.10 The etiology of schizophrenia includes genetic as well as environmental factors. Genome-wide, family-based, adoption, and twin studies revealed a strong association between genetics and schizophrenia.11 A range of environmental factors, from obstetric complications like hypoxia to prenatal infections, season of birth, drug abuse, migrant status, low socioeconomic status, and advanced paternal age, have been implicated in the development and progression of schizophrenia.12 The risk of schizophrenia may also be increased with head injury, autoimmune diseases, epilepsy, and severe infections.12 The most important objectives in treating schizophrenia include managing symptoms, avoiding relapse, and increasing adaptive functioning. Antipsychotic treatment has strong evidence of effectiveness for the treatment of schizophrenia; besides some non-pharmacological approaches, for example, psychosocial therapy, cognitive behavioral therapy, and family education.13,14 Previous studies have shown that more than 1% of the population are prescribed antipsychotic medications. However, around 30–50% of the patients were not responding adequately to the treatment. Several factors have been thought to contribute to treatment failure with antipsychotic drugs. These factors are: clinical factors (age of onset, severity, adherence, comorbidities), demographic factors (gender, living area), environmental factors (smoking, drug use, diet), and genetic factors.15 Family, Twin, and Adoption Studies The risk of schizophrenia is estimated to be 2% for third‑degree relatives, 9% for first‑degree relatives, 27% for children of two affected parents, and 50% for monozygotic twins.16 The risk of schizophrenia for an adopted child of schizophrenic parents is estimated to be 6 to 10 times higher than the general population.16 Again, the risk of developing schizophrenia is the same for children of mothers with schizophrenia, whether healthy families have adopted them or not.17 On the other hand, there is no increased risk of developing schizophrenia in children of healthy parents adopted by a family where one of the parents develops schizophrenia.17 Linkage, Candidate Genes, and Association Studies Linkage analysis is based on the phenomenon that genetic markers physically close on the same chromosome are likely to be inherited together during meiosis, as the process of recombination is less likely to occur between them.17 Many linkage studies of schizophrenia aimed to discover genomic regions in affected extended or nuclear families.17 Linkage studies revealed an association between deletions in region 22q11 and schizophrenia. This region contains two important candidate genes for schizophrenia and bipolar disorder: catechol-O-methyl transferase (COMT) and proline dehydrogenase (PRODH).18 While COMT encodes an important enzyme that plays a role in catecholamine breakdown, PRODH codes for an enzyme that metabolizes L-proline, which is an amino acid that may be directly involved in glutamatergic transmission, one of the middle pathways implicated in schizophrenia.16 Another linkage study found an association between the disrupted in schizophrenia 1 (DISC1) gene resulting from a 1q42 translocation and schizophrenia.16 Candidate gene studies were considered a major approach in schizophrenia genetics before genome-wide association studies (GWAS).19 They are case-control studies employed to measure the correlation between certain genes and the disorder.17 However, after the introduction of GWAS, candidate gene studies became unpopular due to factors related to low power, false positives, low replication rates, insufficient biological knowledge to identify relevant candidate genes, and the increasingly low cost of whole-genome array data.20 Even though, if the sample is adequate, candidate gene studies can detect genes with small-effect alleles.17 The selection of candidate genes is based on their position or functionality. Nowadays, there are more than one thousand candidate genes for schizophrenia that have been tested.17 Due to the polygenic nature of schizophrenia, the majority of its common risk alleles have small effect sizes, which small sample sizes could hinder. Polygenic risk score (PRS) is calculated by summing the association odds ratio of the identified SNPs; the higher the score, the greater the association.21 PRS was highly significant for predicting schizophrenia in the European sample.22 Moreover, schizophrenia PRS can measure bipolar depression due to the shared genetic pathway. Currently, PRS is still considered a weak tool to be used in the clinical diagnosis of schizophrenia. This could be enhanced by increasing the sample size and diversity to increase the PRS.21 Genetic findings should be linked with the phenotype data of the patients, which can show additional factors related to schizophrenia. This was done in a nested case-control design from the Finnish Prenatal Schizophrenia cohort. The cases were followed up with the Finnish registry to know the onset of the first episode, their maternity records, and discharge. About 777 cases were involved because they had enough maternity sera to perform C-reactive protein (CRP) testing, while 737 schizophrenic patients who did not have maternity sera were the controls. There was a significant association between the increase in maternal CRP during pregnancy and schizophrenia in offspring. This study presented strong evidence that maternal inflammation during pregnancy can increase the potential risk of schizophrenia.23 In recent decades, large-scale collaboration has succeeded in identifying loci and alleles with a strong association with schizophrenia.21 Despite this success, GWAS studies are still far from studying rare variants, environmental modifiers, and epigenetic effects. Moreover, most of the studies were conducted on European ancestors, excluding the genetic burden of non-European populations (especially Africans) and limiting the generalisation of the results.21 Replication of the results of GWAS of European ancestors gave different polygenic risk scores in the African-American population. On the other hand, GWAS in the Asian population identified risk alleles similar to those identified in the European ancestor sample; however, the minor allele frequency (MAF) was higher in the Asian sample.24 The application of GWAS on a large case-control sample of European ancestors consisting of 2,663 schizophrenia cases and 13,498 controls from eight European locations collectively called SGENE identified several loci. The strongest loci related to schizophrenia identified in the SGENE sample include zinc finger protein 804A (ZNF804A) (which is a wide area including major histocompatibility complex (MHC) on chromosome 6p21.3–22.1), neurogranin (NRGN) (cognitive function and cortical development; its concentration is reduced in schizophrenic patients,25 and transcription factor 4 (TCF4) (neurocognitive deficit, reduced sensorimotor gating, and earlier onset of schizophrenia.25,26 Another GWAS conducted in a mixed UK-Japanese sample comprising 1990 schizophrenic cases and 5389 controls identified a strong association between sulfonyl transferase family 6B member 1 (SULT6B1) and neurogenic locus notch homolog 4 (NOTCH4) with schizophrenia. SULT6B1 catalyses the sulfonation of xenobiotics, hormones, and neurotransmitters, while NOTCH4 is a gene that encodes the NOTCH4 protein, which exhibits anti-inflammatory activity against activated T-cells. The study also revealed that there is a shared polygenic risk between the Japanese and the Caucasian samples; however, there is a difference in the extent of these risk alleles between populations, which contributes to the failure of replication between different populations.27 On the other hand, the International Consortium of Schizophrenia (ICS) did not identify a large number of strongly associated loci; however, they identified variants with small individual effects, but collectively they affect schizophrenia.28 Ruderfer et al conducted an independent family-based study on 694 parent-offspring schizophrenia trios from Bulgaria; 360 of them were cases in the original ICS manuscript. The result of this study agrees with the ICS polygenic findings.29 The involvement of genes that regulate the immune system in schizophrenia strengthens the immunological hypothesis of schizophrenia.25 A systematic review conducted by Prata et al25 reviewed all independent published GWAS of schizophrenia and bipolar depression from 2011–2019. Of 22 GWAS included in the review, 83 SNPs met the standard significance of the study. These SNPs are located in 28 gene regions. However, only the MHC region, AMBRA1 (autophagy and apoptosis regulator/impulsive behavior), ANK3 (gene encodes ankryn-G protein, membrane-cytoskeleton linker/intellectual disability), ARNTL (transcriptional activation/circadian rhythm disruption), CDH13 (neuronal membrane and signalling molecule/circadian rythm/impulsive behavior), EFHD (Ca+2-sensor for mitochondrial flash activation/neuronal differentiation), PLXNA2 (signal transduction cascade/alters post-natal development of corpus callsom microstructure) and UGT1A1 genes (detoxification enzymes/elimination of 5-HT, DA, antipsychotics, antidepressants, mood stabilizers, and benzodiazepines) have been reported in more than one independent GWAS sample with the same risk allele (except EFHD).25 The Irish Schizophrenia Genomic Consortium and the Wellcome Trust case-control Consortium identified three SNPs of human leukocyte antigen (HLA) in the MHC region with strong association to schizophrenia in a sample of 1606 patients and 1794 controls from Ireland. The allele with the strongest association was HLA-C*01:02. Major histocompatibility complex class I molecules are expressed in the brain and play a role in forming and regulating cortical connectivity across brain circuitry. This study identified HLA alleles that increase the risk of schizophrenia and other HLA alleles that have a protective role against schizophrenia.30 The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium (PGC) conducted a mega-analysis, combining 17 different samples of GWAS, with a total of 9,394 cases and 12,462 controls. They identified seven loci associated with schizophrenia. The first one with the strongest association was at 1p21.3 (rs1625579) near the intron, which contains MIR137, which regulates adult neurogenesis and neuronal maturation. Variation in this locus could play a role in brain development abnormalities in schizophrenia. The second associated locus was 10q24.32, which contains multiple genes. The rest loci were: 8q21.3, 8p23.2, 2q32.3, 6p21.32-p22.1, and 18q21.2.31 Greenwood et al18 conducted a genome-wide association study in which 12 regions were linked to schizophrenia. These regions include several interesting genes such as HTR6 on chromosome 1p36 which encodes for 5-hydroxy tryptamine (serotonin) G-protein coupled receptor 6 (emotion recognition), (ZNF804A) on 2q32, ATXN7 (ataxin7) on 3p14 (the ant saccade task), dopamine transporter (DAT) on 5p15 (prepulse inhibition), Glutamate ionotropic NMDA type subunit 2B (GRIN2B) on 12p12 (face memory), and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAE) on 17p13 (multivariate cognitive phenotype). Other loci express associations with schizophrenia, including 6p24-22, 8p22-21, 13q14.1–32, and 1q21-22.32 Jiaa et al33 examined the association between the GWAS set of genes classified according to their pathways related to schizophrenia. They used the Genetic Association Information Network (GAIN) GWAS dataset. They applied Gene Set Enrichment Analysis (GSEA) and hypergeometric tests, both statistical methods used to measure gene expression and identify pathways overrepresented with significant genes, respectively. The glutamate metabolism pathway was found to have a significant association between the two methods in this study. Moreover, pathways of inflammation and apoptosis were overrepresented by the two methods, including the TNFR1 pathway (protection of neuronal cell death by controlling the binding of TNF-alpha to the TNF receptor 1 that triggers cell apoptosis), and the TGF-beta pathway (neuronal protection against apoptosis and excitotoxicity). Moreover, estrogen and androgen pathways had the smallest p-value using the GESA method. Oestrogen was thought to have a protective role from schizophrenia, as males develop schizophrenia at an earlier age with greater severity.33 Pharmacogenetics and Pharmacogenomics of Antipsychotics Although, in general, differences between individuals in drug treatment response can be caused by environmental, physiological, and psychological factors, as well as by co-morbidities, one can estimate that roughly one-quarter of the total variability in drug response is genetic in origin.34 That is why clinicians adopt a “trial and error” procedure until optimal treatment is found.35 However, failure of antipsychotic treatment has considerable clinical and economic costs. Even though a delay in finding adequate therapy for psychotic patients hurts the patient’s prognosis and recovery.15 The “Trial and error” approach can lead to serious adverse effects like suicidal ideation and behavioral changes before getting suitable treatment.34 Drug response is affected by a variety of genetic variants across multiple pathways involved in drug metabolism and activity. Therefore, it is uncommon for a single genetic variant to reliably predict drug response on its own.35 Pharmacogenetics and pharmacogenomics leverage genomic data to predict drug response, metabolism, and side effects, thereby streamlining the medication selection process for psychiatrists.36,37 Pharmacogenetics refers to the study of how a specific gene or set of genes influences a patient’s response to medication. In contrast, pharmacogenomics examines how a patient’s entire genetic makeup affects their response to drugs. However, these terms are sometimes used interchangeably.38 Before the appearance of GWAS or next-generation sequencing, which are considered pharmacogenomics approaches, studies investigating drug response or adverse effects have used the candidate gene approach, ie, the pharmacogenetics approach. Nowadays, GWAS and next-generation sequencing play an important role in transferring genetic findings into clinical practice.39 Pharmacogenetic studies found a strong association between polymorphisms in liver cytochrome metabolizing enzymes (CYP enzymes) and variation in antipsychotic drug response and the development of adverse effects. Moreover, genetic variants in dopamine and serotonin neurotransmitters and their receptors were also reported to affect antipsychotic response.15 Variations in CYP1A1 and CYP2C9 genes were associated with adverse effects like somnolence and neurological events for healthy volunteers using quetiapine. Moreover, variation in CYP1A2 was associated with higher plasma concentration and better response to olanzapine. Tardive dyskinesia (TD) development also increased with variation in CYP1A2 and CYP2D6 genes. CYP2D6 metabolizes risperidone; intermediate and poor metabolizers suffer from adverse effects of risperidone. However, ultrarapid metabolizers of CYP2C19 are protected against complications of clozapine. Pre-treatment genotyping for CYP enzymes can be used to select the right drug with the appropriate dose to the patients. This method was found to increase the efficacy and tolerability of antipsychotics.15 On the other hand, polymorphism in uridine diphosphate glucuronosyltransferase (UGT) was found to affect olanzapine tolerability. Variations in ABCB1 and ABCC were associated with the development of weight gain in patients treated with clozapine, and QTc prolongation with antipsychotic treatment.15 Regarding the pharmacodynamics area, variations in dopamine receptor type D2 and D3 were associated with variations in outcomes of antipsychotics and side effects (movement disorder). Additionally, polymorphisms in serotonin receptors type 2A, 2C, and 6 were associated with variation in response of SGAs, TD (5-HTR2C and 5-HTR2A), and weight gain (5-HTR2C). Nonetheless, mutations in glutamatergic receptors were found to affect the efficacy of antipsychotics. Clinical applications of genotyping dopamine and serotonin receptors are limited due to their modest impact on the response.15 Many factors limit the implementation of pharmacogenetics in psychiatric hospitals. These factors include a lack of facilities to perform genetic testing, lack of information on the clinical and economic benefits of actionable pharmacogenetic tests, lack of clinical intervention protocols, length of delivery time of results, and cost of tests.15 McClay et al40 used a genome-wide approach to detect genetic variation underlying individual differences in response to treatment with the different antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone, and perphenazine). The outcome of antipsychotics was assessed by positive and negative symptoms score (PANSS). The most significant association was with rs12860002 at HTR2A, which mediated the effects of quetiapine on negative symptoms. Moreover, the study identified several markers close to the FMO5 locus that showed an association for mediating the effects of quetiapine on emotional distress symptoms. The study also identified SNPs located in three genes. These genes were the Ankyrin Repeat and Sterile Alpha Motif Domain-Containing Protein 1B (ANKS1B), the Contactin-Associated Protein-Like 5 gene (CNTNAP5), and Transient Receptor Potential Cation Channel, subfamily M, member 1 (TRPM1). These SNPs need more investigation to know their effect on antipsychotics.40 Aberg et al41 Conducted a GWAS in a sample of 738 schizophrenic patients who were genotyped for 492 thousand SNPs to search for genetic susceptibility to EPS. EPS was measured using three different measures. Simpson-Angus scale (SAS) for parkinsonism, the Barnes Akathisia rating scale, and the abnormal involuntary movement scale (AIMS), as well as a clinical diagnosis of probable tardive dyskinesia. One of the SNPs that reached genome-wide significance is rs2126709. rs2126709 was located in the 3’UTR of ZNF202, which controls promoter elements found in, for example, apolipoprotein E (apoE), lipoprotein lipase (LPL), ATP binding cassette (ABC) transporters A1 and G1, proteolipid protein (PLP) and early growth response 3 (EGR3). ZNF202 has been associated with dyslipidemia, high-density lipoprotein control, and many genes under its control are involved in reverse cholesterol transport. Decreased expression of PLP1 was associated with movement disorders like ataxia.41 In Sudan, till now, we do not have sufficient data either about the genetics of schizophrenia or genetic variables affecting antipsychotic medications. Accordingly, conducting research in mental health areas in Sudanese patients can increase awareness and care for this category of patients; also, it can uncover obstacles in psychiatric management in Sudan. Our study aimed to screen different genes that affect schizophrenia treatment in Sudanese patients. Method Study Design This study is a case-control family-based study targeting Sudanese families with siblings affected by schizophrenia according to DSM-IV or ICD-10 diagnostic criteria. The method was described comprehensively in our previous paper. Participants This study was conducted on seven Sudanese families with more than one member diagnosed with schizophrenia according to DSM-IV or ICD-10 diagnostic criteria. It involved genotyping of both patients and controls within the families. The study was conducted between March 2017 and December 2022. All the details are found in this article.42 The gene sequencing method was used to determine the genotype of both schizophrenic patients and normal family members (controls) as follows: Family one: two male schizophrenic patients and their healthy brother (control). Family two: two schizophrenic sisters, an unaffected brother, and a sister as controls. Family three: one schizophrenic male, one schizophrenic female, and their normal brother. Family four: two schizophrenic males and their normal brother. Family five: three schizophrenic males, one schizophrenic female, and their normal sister. Family six: four schizophrenic female sisters and their normal brother. Family seven: two schizophrenic sisters and their normal brother as a control. Samples and DNA Extraction Participants’ full demographic data, disease, and medication history were collected by a pre-designed data collection sheet. Then, Sterile syringes were used to collect venous blood samples (10 mL) in EDTA vacutainer tubes from both patients and controls. Standard techniques were applied to prevent contamination. Each blood sample (10 mL) was transferred to a 15 mL Falcon tube. Then, 10 mL of red blood cell lysis buffer (RCLB) (0.08 mL Ammonium bicarbonate and 6.1 mL ammonium chloride dissolved in one liter of distilled water) were added and mixed gently. After that, the tubes were spun for 5 minutes at 3000 rpm. This step was repeated multiple times until a white pellet was obtained after discarding the supernatant. Subsequently, 2 mL of white blood cell lysis buffer (WCLB) (5 µL of 10 mg/mL proteinase K, 1 mL of 6 M guanidine chloride, and 300 µL of 7.5 M Ammonium acetate) was added to the pellet in 15 mL Falcon tube. The tubes were left overnight at 37°C autoclave. Once the digestion step was complete, the tubes were allowed to cool to room temperature. The samples were then transferred into another 15 mL Falcon tube containing 2 mL pre-chilled chloroform, vortexed, and centrifuged at 3000 rpm for 15 min. After removing the supernatant, the tubes were left inverted on tissue paper for at least one hour. Next, the DNA pellets were resuspended in 200 µL ddH2O, vortexed, and kept at 4°C overnight. The extracted DNA was stored at −20 °C. DNA concentrations were measured using a NanoDrop spectrophotometer and adjusted to 30 ng/μL. The absorbance ratio at 260 nm to 280 nm was utilized to assess DNA purity, with a ratio of approximately 1.8 generally considered as indicating pure DNA. One microliter of the sample was pipetted onto the end of a fiber optic cable (the receiving fiber). A second fiber optic cable (the source fiber) was then brought into contact with the liquid sample, causing the liquid to bridge the gap between the ends of the fiber optics. The gap distance was controlled to both 1 mm and 0.2 mm paths. A pulsed xenon flash lamp served as the light source, and a spectrometer equipped with a linear CCD array was employed to analyse the light after it passed through the sample. The instrument was operated via specialized software running on a PC, and the data was logged in an archive file stored on the PC. Next-Generation Sequences All the samples were sent to the Beijing Genomic Institute (BGI), Hong Kong. BGI performs sequencing according to the service agreement, which includes generating at least 90 GB/sample and data cleaning. The samples belonging to the first family were sent for whole-exome sequencing, while the other six families were sent for whole-genome sequencing (WGS) (BGISEQ Human Whole Genome Sequencing). The samples were sequenced using Illumina HiSeq2000 platforms at Beijing Genomic Institute (BGI), Hong Kong. Quality control was also done through BGI according to the contract. To obtain “Clean Reads” for bioinformatics analysis, the following types of reads were removed: those containing adaptor sequences (13 bp), reads with a high proportion of unknown bases (more than 10%), and low-quality reads. Alignment to the reference genome (UCSC build HG 19) was done using BWA (BWA software).43 Duplicates were marked using the Picard tool. The alignments were combined using one BAM file. The BAM file is the compressed form of the Sequence Alignment/Map format (SAM).44 SNPs and indels were called using the GATK tool. Each variant was then annotated to the corresponding gene functional units in the RefGene database, including nucleotide and amino acid changes. Validation and comparison of SNPs and indels were conducted using the dbSNP database and the 1000 Genomes Project database. The final Variant Call Format (VCF) files were received and prepared for gene prioritization. The initial filtering process focused on variants shared among patients within each family but not present in controls. Each family was analyzed as a separate unit to identify potential connections between them. To compare variants (SNP, InDel, CNV, SV) shared among cases and absent in controls, the R programming package was utilized. The used scripts were: {Library(plyr) / RESULT 1<- match_df(CASE 1,CASE2, on =“Transcript”) / FINALRESULT <- subset(RESULT, !(Transcript %in% CONTROL$Transcript))}. Gene Filtering Analysis From the whole genome (WGS) and whole exome (WES) Variant Call Format (VCF) files of both patients and controls, the variant filtering process commenced by identifying variants shared exclusively between patients within the same family and not present in their unaffected siblings (using R programming). This filtering applied to both SNPs and INDELs was based on the variant transcript or position. Subsequently, these shared variants among patients were further filtered based on their impact classification, categorized as High, Moderate, Modifier, or Low impacts, and primarily determined by the gene function annotated during BGI Basic Bioinformatics Analysis. Intronic, intergenic variants, and pseudogenes were excluded, while variants classified as High and Moderate impact damaging were retained. An analysis focused on specific groups of genes involved extracting their data from the VCF files using UNIX commands to grep all relevant gene information. After receiving the Variant Calling Files (VCF) from BGI, the data were processed using Linux software commands. Sixty‑six candidate genes that have roles in pharmacokinetics, pharmacodynamics, and resistance of antipsychotics were identified from the VCF of the cases and the controls (Table 1).45,46. The resulting files were processed using the R software package to find variants that are shared between cases in each family; these variants were compared with the controls. In addition, shared variants between all the cases were identified. From these variants, high-impact and moderate-impact factor variants were selected. Table 1Selected Candidate Genes Affecting Pharmacokinetics, Pharmacodynamics, and Resistance of Antipsychotics, Plus Genes Related to SchizophreniaNo.GeneGene NameUniprot IDRoleComment1.ABCC1ATP-binding cassette Subfamily C member 1P33527Antipsychotics Carrier2.ABCB1Multidrug resistance–associated protein 1P08183Antipsychotics Carrier3.ADRA1AAdrenoceptor alpha1aP35348Antipsychotics Target4.ADRA2AAdrenoceptor alpha2aP08913Antipsychotics Target5.BDNFBrain-derived neurotrophic factorP23560Schizophrenia6.CHRM1Cholinergic receptor muscarinic 1P22119Antipsychotics target7.CHRM2Muscarinic acetylcholine receptor M2P08192Antipsychotics target8.CHRM3Cholinergic receptor muscarinic 3P20309Antipsychotics target9.CHRM4Cholinergic receptor muscarinic 4P08173Antipsychotics target10.CHRM5Cholinergic receptor muscarinic 5P08912Antipsychotics target11.CYP1A2Cytochrome P450 1A2P05177Metabolizing enzymeOlanzapine Clozapine12.CYP2C9Cytochrome P450 2C9P11712Metabolizing enzyme13.CYP2D6Cytochrome P450 2D6P10635Metabolizing enzymeRisperidone14.CYP3A4Cytochrome P450 3A4P08684Metabolizing enzymeQuetiapine15.CYP2C19Cytochrome P450 2C19P33261Metabolizing enzyme16.CYP2E1Cytochrome P450 2E1P05181Metabolizing enzyme17.CYP2JCytochrome P450 2JP51589Metabolizing enzyme18.CYP2C8Cytochrome P450 2C8/9P10632Metabolizing enzyme19.DRD1Dopamine receptor D1P21728Antipsychotics target20.DRD2Dopamine receptor D2P14416Antipsychotics target21.DRD3Dopamine receptor D3P35462Antipsychotics target22.DRD4Dopamine receptor D4P21917Antipsychotics target23.DTNBP1Dystrobrevin-binding protein1Q96EV8Schizophrenia Biomarker24.FOSFOS proto-oncogeneP01100Schizophrenia Biomarker25.GRIN2BGlutamate receptor ionotropic, NMDA 2BQ01097Schizophrenia Biomarker26.GSTP1Glutathione S-transferase pi geneP09211Antipsychotics side-effects27.HRH1Histamine H1 receptorP35367Antipsychotics target28.HTR2ASerotonin receptor 2AP28223Antipsychotics target29.HTR2BSerotonin receptor 2BP41595Antipsychotics target30.HTTSerotonin transporter geneP42858Antipsychotics target31.ILIRNInterleukin-1 receptor antagonist proteinP18510Schizophrenia32.KCNE1Potassium voltage-gated channel subfamily E regulatory subunit 1P15382Antipsychotics side-effectsQTC prolongation33.KCNE2Potassium voltage-gated channel subfamily E regulatory subunit 2Q9Y6J6Antipsychotics side-effectsQTC prolongation34.KCNH2Potassium voltage-gated channel subfamily H member 2Q12809Antipsychotics side-effects SchizophreniaQTC prolongation35.KCNJ11ATP-sensitive inward rectifier potassium channel 11Q14654Antipsychotics side-effectsWeight gain36.KCNQ1Potassium voltage-gated channel subfamily KQT member 1P51787Antipsychotics side-effectsQTC prolongation37.SCN5ASodium channel protein type 5 subunit alphaQ14524Antipsychotics side-effectsQTC prolongation38.UGTSUDP-glucuronosyltransferase 2A1PTE4Antipsychotics biotransformation39.ADRB3Beta-3 adrenergic receptor P13945Antipsychotics target40.APOA5Apolipoprotein A 5Q6Q788Antipsychotics side-effectsElevated serum TGs*41.APOC3Apolipoprotein C-IIIP02656Antipsychotics side-effectsElevated serum TGs*42.COMTCatechol-o-methyltransferaseP21964Schizophrenia AntipsychoticsCognition43.FMO1Flavin containing monooxygenase 1Q01740Antipsychotics biotransformation44.GNB3Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3P16520Antipsychotics weight gain and obesity45.GRM3Glutamate receptor 3Q14832Antipsychotics target46.HRH2Histamine H2 receptorP25021Antipsychotics target47.HTR1ASerotonin receptor 1AP08908Antipsychotics target48.HTR1BSerotonin receptor 1BP28222Antipsychotics target49.HTR1DSerotonin receptor 1DP28221Antipsychotics target50.HTR1ESerotonin receptor 1EP28566Antipsychotics target51.HTR2CSerotonin receptor 2CP28335Antipsychotics target52.HTR3ASerotonin receptor 3AP46098Antipsychotics target53.HTR6Serotonin receptor 6P50406Antipsychotics target54.HTR7Serotonin receptor 7P34969Antipsychotics target55.KCNH2Potassium voltage-gated channel subfamily H member 2Q12809Antipsychotics side-effectsQTC prolongation56.LEPLeptinP41159Antipsychotics side-effectsWeight gain57.LEPRLeptin receptor precursorP48357Antipsychotics side-effectsWeight gain58.LPLLipoprotein lipaseP06858Antipsychotics side-effectsWeight gain59.RGS2Regulator of G-protein signaling 2P41220Antipsychotics side-effects*EPS60.SLC6A2Sodium-dependent noradrenaline transporterP23975Antipsychotics targetRisperidone Olanzapine61.TNFTumor necrosis factorP50591Schizophrenia62.UGT1A4UDP-glucuronosyltransferase family 1 member 3P22310Antipsychotics biotransformation63.FABP1Fatty acid-binding protein 1P07148Antipsychotics side-effectsWeight gain64.PON1Paraoxonase and arylacetate 1P27169Schizophrenia65.RGS4Regulator of G-protein signaling 4P49798Antipsychotics side-effects**EPS66.SLC6A4Sodium-dependent noradrenaline transporterP31645Antipsychotics targetAbbreviations: *TGs, Triglycerides; **EPS, Extrapyramidal Symptoms. Table 1Selected Candidate Genes Affecting Pharmacokinetics, Pharmacodynamics, and Resistance of Antipsychotics, Plus Genes Related to SchizophreniaNo.GeneGene NameUniprot IDRoleComment1.ABCC1ATP-binding cassette Subfamily C member 1P33527Antipsychotics Carrier2.ABCB1Multidrug resistance–associated protein 1P08183Antipsychotics Carrier3.ADRA1AAdrenoceptor alpha1aP35348Antipsychotics Target4.ADRA2AAdrenoceptor alpha2aP08913Antipsychotics Target5.BDNFBrain-derived neurotrophic factorP23560Schizophrenia6.CHRM1Cholinergic receptor muscarinic 1P22119Antipsychotics target7.CHRM2Muscarinic acetylcholine receptor M2P08192Antipsychotics target8.CHRM3Cholinergic receptor muscarinic 3P20309Antipsychotics target9.CHRM4Cholinergic receptor muscarinic 4P08173Antipsychotics target10.CHRM5Cholinergic receptor muscarinic 5P08912Antipsychotics target11.CYP1A2Cytochrome P450 1A2P05177Metabolizing enzymeOlanzapine Clozapine12.CYP2C9Cytochrome P450 2C9P11712Metabolizing enzyme13.CYP2D6Cytochrome P450 2D6P10635Metabolizing enzymeRisperidone14.CYP3A4Cytochrome P450 3A4P08684Metabolizing enzymeQuetiapine15.CYP2C19Cytochrome P450 2C19P33261Metabolizing enzyme16.CYP2E1Cytochrome P450 2E1P05181Metabolizing enzyme17.CYP2JCytochrome P450 2JP51589Metabolizing enzyme18.CYP2C8Cytochrome P450 2C8/9P10632Metabolizing enzyme19.DRD1Dopamine receptor D1P21728Antipsychotics target20.DRD2Dopamine receptor D2P14416Antipsychotics target21.DRD3Dopamine receptor D3P35462Antipsychotics target22.DRD4Dopamine receptor D4P21917Antipsychotics target23.DTNBP1Dystrobrevin-binding protein1Q96EV8Schizophrenia Biomarker24.FOSFOS proto-oncogeneP01100Schizophrenia Biomarker25.GRIN2BGlutamate receptor ionotropic, NMDA 2BQ01097Schizophrenia Biomarker26.GSTP1Glutathione S-transferase pi geneP09211Antipsychotics side-effects27.HRH1Histamine H1 receptorP35367Antipsychotics target28.HTR2ASerotonin receptor 2AP28223Antipsychotics target29.HTR2BSerotonin receptor 2BP41595Antipsychotics target30.HTTSerotonin transporter geneP42858Antipsychotics target31.ILIRNInterleukin-1 receptor antagonist proteinP18510Schizophrenia32.KCNE1Potassium voltage-gated channel subfamily E regulatory subunit 1P15382Antipsychotics side-effectsQTC prolongation33.KCNE2Potassium voltage-gated channel subfamily E regulatory subunit 2Q9Y6J6Antipsychotics side-effectsQTC prolongation34.KCNH2Potassium voltage-gated channel subfamily H member 2Q12809Antipsychotics side-effects SchizophreniaQTC prolongation35.KCNJ11ATP-sensitive inward rectifier potassium channel 11Q14654Antipsychotics side-effectsWeight gain36.KCNQ1Potassium voltage-gated channel subfamily KQT member 1P51787Antipsychotics side-effectsQTC prolongation37.SCN5ASodium channel protein type 5 subunit alphaQ14524Antipsychotics side-effectsQTC prolongation38.UGTSUDP-glucuronosyltransferase 2A1PTE4Antipsychotics biotransformation39.ADRB3Beta-3 adrenergic receptor P13945Antipsychotics target40.APOA5Apolipoprotein A 5Q6Q788Antipsychotics side-effectsElevated serum TGs*41.APOC3Apolipoprotein C-IIIP02656Antipsychotics side-effectsElevated serum TGs*42.COMTCatechol-o-methyltransferaseP21964Schizophrenia AntipsychoticsCognition43.FMO1Flavin containing monooxygenase 1Q01740Antipsychotics biotransformation44.GNB3Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3P16520Antipsychotics weight gain and obesity45.GRM3Glutamate receptor 3Q14832Antipsychotics target46.HRH2Histamine H2 receptorP25021Antipsychotics target47.HTR1ASerotonin receptor 1AP08908Antipsychotics target48.HTR1BSerotonin receptor 1BP28222Antipsychotics target49.HTR1DSerotonin receptor 1DP28221Antipsychotics target50.HTR1ESerotonin receptor 1EP28566Antipsychotics target51.HTR2CSerotonin receptor 2CP28335Antipsychotics target52.HTR3ASerotonin receptor 3AP46098Antipsychotics target53.HTR6Serotonin receptor 6P50406Antipsychotics target54.HTR7Serotonin receptor 7P34969Antipsychotics target55.KCNH2Potassium voltage-gated channel subfamily H member 2Q12809Antipsychotics side-effectsQTC prolongation56.LEPLeptinP41159Antipsychotics side-effectsWeight gain57.LEPRLeptin receptor precursorP48357Antipsychotics side-effectsWeight gain58.LPLLipoprotein lipaseP06858Antipsychotics side-effectsWeight gain59.RGS2Regulator of G-protein signaling 2P41220Antipsychotics side-effects*EPS60.SLC6A2Sodium-dependent noradrenaline transporterP23975Antipsychotics targetRisperidone Olanzapine61.TNFTumor necrosis factorP50591Schizophrenia62.UGT1A4UDP-glucuronosyltransferase family 1 member 3P22310Antipsychotics biotransformation63.FABP1Fatty acid-binding protein 1P07148Antipsychotics side-effectsWeight gain64.PON1Paraoxonase and arylacetate 1P27169Schizophrenia65.RGS4Regulator of G-protein signaling 4P49798Antipsychotics side-effects**EPS66.SLC6A4Sodium-dependent noradrenaline transporterP31645Antipsychotics targetAbbreviations: *TGs, Triglycerides; **EPS, Extrapyramidal Symptoms. Selected Candidate Genes Affecting Pharmacokinetics, Pharmacodynamics, and Resistance of Antipsychotics, Plus Genes Related to Schizophrenia Abbreviations: *TGs, Triglycerides; **EPS, Extrapyramidal Symptoms. After this step, a variant network was established using databases like Cytoscape,47 Clinvar,48 Consensuspath,49 and Enricher50 databases. Allele frequencies of the variants with high impact in different races and populations were searched in the Ensembl database.51 Ethical Approval This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The proposal for this study was submitted to the University of Khartoum Medical Campus Ethical Committee, as well as the Ministry of Health Ethical Committee-Khartoum, Sudan. Ethical approval was obtained (No. 5–10-19, 22 October 2019). Moreover, informed consents were signed by the patients and their guardians. All the data were anonymized to ensure confidentiality. Result This study was a case-control descriptive study involving seven Sudanese families with more than one member diagnosed with schizophrenia. Eighteen patients and 8 controls were included in the study. This study was hypothesis-generating. Next-generation sequencing was used to investigate schizophrenia in the families involved in the study. Demographic data of the participants are shown in Table 2. Table 2Illustrates the Demographic Data of Schizophrenic Patients Involved in the StudyVariableMinimumMaximumAge1758VariableFrequencyGenderMale8 (44.4%)Female10 (55.6%)EducationPrimary school5 (27.8%)Secondary school7 (38.9%)University4 (22.2%)BSC2 (11.1)Marital statusSingle15 (83.3%)Married1 (5.6%)Divorced2 (11.1%)JobYes4 (22.2%)No14 (77.8%)ResidenceKhartoum14 (77.8%)Others4 (22.2%)Socioeconomic statusGood7 (38.9%)Average4 (22.2%)Poor7 (38.9%) Table 2Illustrates the Demographic Data of Schizophrenic Patients Involved in the StudyVariableMinimumMaximumAge1758VariableFrequencyGenderMale8 (44.4%)Female10 (55.6%)EducationPrimary school5 (27.8%)Secondary school7 (38.9%)University4 (22.2%)BSC2 (11.1)Marital statusSingle15 (83.3%)Married1 (5.6%)Divorced2 (11.1%)JobYes4 (22.2%)No14 (77.8%)ResidenceKhartoum14 (77.8%)Others4 (22.2%)Socioeconomic statusGood7 (38.9%)Average4 (22.2%)Poor7 (38.9%) Illustrates the Demographic Data of Schizophrenic Patients Involved in the Study Regarding patients’ treatment, the duration of treatment varied between a minimum of 4 months and a maximum duration of 32 years. Second-generation antipsychotics were used more frequently than first-generation antipsychotics in this sample of patients. Risperidone was the most frequently used antipsychotic (44.4%), while only two patients were using haloperidol. LAIs were used by 16.7% of the patients, whereas electroconvulsive therapy (ECT) was experienced by 11.1% of the patients. Adjunctive therapy (such as promethazine and sodium valproate) was used by 77.8% of the patients. Adherence to antipsychotic use varies between participants, from good (66.6%), average (5.6%), and poor (27.8%). Only 55.6% reported the presence of side effects (Table 3). Table 3Exhibits the Treatment of the Patients Involved in the StudyVariableMinimumMaximumDuration of treatment4 months32 yearsVariableFrequencyType of treatmentOlanzapine6 (33.3%)Risperidone8 (44.4%)Haloperidol2 (11.1%)LAI3 (16.7%)ECT2 (11.1%)Promethazine9 (50%)Sodium valproate5 (27.8%)AdherenceGood12 (66.6%)Average1 (5.6%)Poor5 (27.8%)Side effectsYes10 (55.6%)No8 (44.4%) Table 3Exhibits the Treatment of the Patients Involved in the StudyVariableMinimumMaximumDuration of treatment4 months32 yearsVariableFrequencyType of treatmentOlanzapine6 (33.3%)Risperidone8 (44.4%)Haloperidol2 (11.1%)LAI3 (16.7%)ECT2 (11.1%)Promethazine9 (50%)Sodium valproate5 (27.8%)AdherenceGood12 (66.6%)Average1 (5.6%)Poor5 (27.8%)Side effectsYes10 (55.6%)No8 (44.4%) Exhibits the Treatment of the Patients Involved in the Study High-Impact Genes Regarding this study, after selecting 66 candidate genes for schizophrenia and antipsychotic treatment from VCF, there was no difference between cases and controls in each family in the presentation. Additionally, no single variant was shared among all the families. However, a collection of 12 variants was identified as high-impact variants in all families. The most frequent gene among them was COMT with a total of 5 variants (Tables 4, 5). Table 4Distribution of High-Impact Variants in Different Families Involved in the StudyFamily 1Family 2Family 3Family 4Family 5Family 6Family 7GenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsCOMTrs4633COMTrs4633CYP2C9rs28371685COMTrs4633CYP2C9rs28371685CYP2C9rs28371685ABCC1rs16967755COMTrs4680COMTrs4680GRM3rs274624COMTrs4680GRM3rs274624GRM3rs274624COMTrs4818COMTrs199710929FMO1rs10912675FMO1rs10912675GRM3rs274624COMTrs740602GRM3rs274624FMO1rs10912675ABCC1rs16967755LPLrs328CYP2E1rs6413419 Table 5Genes with High-Impact Obtained from Families Involved in the StudyNo.GeneAlleleType1.COMTrs48182.COMTrs46333.COMTrs7406024.COMTrs199710929D*5.COMTrs46806.COMTrs1656317.FMO1rs109126758.LPLrs3289.CYP2E1rs641341910.ABCC1rs1696775511.GRM3rs27462412.CYP2C9rs28371685D*Notes: *Type is identified according to SIFT and PolyPhen-2 scores, D: damaging. Table 4Distribution of High-Impact Variants in Different Families Involved in the StudyFamily 1Family 2Family 3Family 4Family 5Family 6Family 7GenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsGenesVariantsCOMTrs4633COMTrs4633CYP2C9rs28371685COMTrs4633CYP2C9rs28371685CYP2C9rs28371685ABCC1rs16967755COMTrs4680COMTrs4680GRM3rs274624COMTrs4680GRM3rs274624GRM3rs274624COMTrs4818COMTrs199710929FMO1rs10912675FMO1rs10912675GRM3rs274624COMTrs740602GRM3rs274624FMO1rs10912675ABCC1rs16967755LPLrs328CYP2E1rs6413419 Distribution of High-Impact Variants in Different Families Involved in the Study Table 5Genes with High-Impact Obtained from Families Involved in the StudyNo.GeneAlleleType1.COMTrs48182.COMTrs46333.COMTrs7406024.COMTrs199710929D*5.COMTrs46806.COMTrs1656317.FMO1rs109126758.LPLrs3289.CYP2E1rs641341910.ABCC1rs1696775511.GRM3rs27462412.CYP2C9rs28371685D*Notes: *Type is identified according to SIFT and PolyPhen-2 scores, D: damaging. Genes with High-Impact Obtained from Families Involved in the Study Notes: *Type is identified according to SIFT and PolyPhen-2 scores, D: damaging. Although the association of our variants with schizophrenia is not yet confirmed, these genes still demonstrated a statistically significant association with schizophrenia according to various databases (Table 6). Table 6Allele Frequency of High-Impact Variants Among Different Populations (Ensembl Database Accessed in November 2022)51NoGeneVariantAllele FrequencyImpactAll PopAFRAMRAESEURSAS1.COMTrs48180.13High0.30.170.30.340.40.312.COMTrs46330.53High0.370.290.380.270.50.453.COMTrs7406020.11High0.060.200.0200.0090.0124.COMTrs46800.49High0.370.280.380.280.50.445.FMO1rs109126750.45High0.420.770.340.190.280.386.LPLrs3280.1High0.090.060.060.120.130.097.CYP2E1rs64134190.11High0.080.240.0400.030.018.ABCC1rs169677550.29High0.310.420.170.310.240.359.COMTrs1656310.04High0.0100.0100.020.0210.GRM3rs2746240.79High0.810.810.820.90.640.8911.CYP2C9rs283716850.06High0.010.020000Abbreviations: Pop, population; AFR, African; AMR, American; AES, East Asian; EUR, European; SAS, South Asian. Table 6Allele Frequency of High-Impact Variants Among Different Populations (Ensembl Database Accessed in November 2022)51NoGeneVariantAllele FrequencyImpactAll PopAFRAMRAESEURSAS1.COMTrs48180.13High0.30.170.30.340.40.312.COMTrs46330.53High0.370.290.380.270.50.453.COMTrs7406020.11High0.060.200.0200.0090.0124.COMTrs46800.49High0.370.280.380.280.50.445.FMO1rs109126750.45High0.420.770.340.190.280.386.LPLrs3280.1High0.090.060.060.120.130.097.CYP2E1rs64134190.11High0.080.240.0400.030.018.ABCC1rs169677550.29High0.310.420.170.310.240.359.COMTrs1656310.04High0.0100.0100.020.0210.GRM3rs2746240.79High0.810.810.820.90.640.8911.CYP2C9rs283716850.06High0.010.020000Abbreviations: Pop, population; AFR, African; AMR, American; AES, East Asian; EUR, European; SAS, South Asian. Allele Frequency of High-Impact Variants Among Different Populations (Ensembl Database Accessed in November 2022)51 Abbreviations: Pop, population; AFR, African; AMR, American; AES, East Asian; EUR, European; SAS, South Asian. Then, the allele frequency of high-impact genes was determined in different populations using the Ensembl database accessed in November 202251 (Table 5). Indel Mutation Concerning Indel mutations, two genes are involved: CYP2D6 and DTNBP1 (Table 7). These genes were associated with schizophrenia (p-value 0.004741) (Tables 8,9). Table 7Correlations Between High-Impact Genes Obtained from Families Involved in the Study and Diseases According to Different Databases (Accessed in March 2022)48,52Clinvar 2019 DatabaseOMIM Disease DatabaseDiseaseP-valueDiseaseP-valueHyperproteinemia0.002797Cholesterol level0.005239Schizophrenia0.006632Schizophrenia0.01045 Table 8Indel Mutations Were Obtained from the Families Involved in the StudyGeneVariantCYP2D6rs763609904DTNBP1rs35477518 Table 9Correlation Between Indel Mutations Obtained from Families Involved in the Study and Diseases (Clinvar 2019 Database Accessed in March 2022)48DiseaseP-valueHermansky-Pudlak syndrome0.002498Schizophrenia0.004741 Table 7Correlations Between High-Impact Genes Obtained from Families Involved in the Study and Diseases According to Different Databases (Accessed in March 2022)48,52Clinvar 2019 DatabaseOMIM Disease DatabaseDiseaseP-valueDiseaseP-valueHyperproteinemia0.002797Cholesterol level0.005239Schizophrenia0.006632Schizophrenia0.01045 Correlations Between High-Impact Genes Obtained from Families Involved in the Study and Diseases According to Different Databases (Accessed in March 2022)48,52 Table 8Indel Mutations Were Obtained from the Families Involved in the StudyGeneVariantCYP2D6rs763609904DTNBP1rs35477518 Indel Mutations Were Obtained from the Families Involved in the Study Table 9Correlation Between Indel Mutations Obtained from Families Involved in the Study and Diseases (Clinvar 2019 Database Accessed in March 2022)48DiseaseP-valueHermansky-Pudlak syndrome0.002498Schizophrenia0.004741 Correlation Between Indel Mutations Obtained from Families Involved in the Study and Diseases (Clinvar 2019 Database Accessed in March 2022)48 Discussion This study was conducted in seven Sudanese families with more than one member affected by schizophrenia. The study was a descriptive case-control hypothesis-generating study aimed at identifying variants and genes that played a role in the development of schizophrenia or affected its treatment. Whole-exome/genome sequencing was performed on the samples. Analysis of big data, like the whole exome/genome data, yields a variety of DNA variant types, including single-nucleotide polymorphisms (SNPs) and small insertions and deletions, which could be of a drastic (frameshift), moderate (missense), or mild (silent) effect on the encoded protein.53 Genetic polymorphism is defined as a stable variation in a given locus of genetic sequence; this variation should be detected in 1% or more of the population.54 Interpretation of these variants’ effects is complex and could be identified by determining the variant’s impact. Variants’ impact is determined by their effect on the coding potential of the transcript. High-impact variants are the variants that can lead to the loss of function of the encoded protein. Moderate-impact variants are the variants that can either lead to a remarkable change in the protein, ranging from loss of stability to impaired activity of the encoded protein, or they can lead to tolerated effects. Low-impact variants are those that can exert change through the alteration of the regulatory motifs (short nucleotide sequence controls the expression of genes).53 Coding region mutations include: silent mutation, which can change the codon without a consequent change in the amino acid; missense mutation resulting from the substitution of a single nucleotide base, which can alter the codon and lead to the coding of a different amino acid; nonsense mutation, which produces premature termination of translation by changing a functional codon into a stop codon.55 Analysis of the current study clarified that the participating families are not genetically similar, as they belong to different tribes and races. No single variant was shared between the seven families. This finding is considered normal in a population with a large effective population size, like the Sudanese population. Ibrahim56 mentioned that Africans, particularly Sudanese, possess a large effective population size (Ne). This mathematical term explains the level of genetic diversity. Large population size can increase the chance of survival from different dangers; however, this could be challenging for genomics research and practice, especially for the future of individualized medicine.56 Again, there was no difference between cases and controls regarding the mutations and frequency of the genes in this study. This study identified twelve variants of seven genes (COMT, FMO1, LPL, CYP2E1, ABCC1, GRM3, CYP2C9) with high impact, having an association with schizophrenia (p-value=0.006632). These variants are mostly protein-coding (COMT rs633, rs4818, rs6480, rs165631, rs740602, rs199710929, GRM3 rs274624, CYP2C9 rs28371685, and CYP2E1 rs6413419), while FMO1 rs10912675 and ABCC1 rs16967755 were missense variants, and LPL rs328 was nonsense variant. A protein-coding variant affects the amino acid sequence in the coding region of a gene, resulting in a change of structure, stability, or function of a protein, which can increase the risk and progression of diseases.57 Among the five variants of COMT, rs4818, rs4680, and rs4633 were known to have associations with schizophrenia.58–60 Again, haplotype 4818–4680 was found to decrease PANSS in patients using olanzapine.58 Moreover, COMT rs199710929 and CYP2C9 rs28371685 were classified as damaging variants according to Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping v2 (PolyPhen-2). SIFT and PolyPhen-2 are bioinformatics tools developed to detect whether nonsynonymous changes in the amino acid sequence will affect protein structure and function. However, SIFT and PolyPhen-2 predictions were not usually reflected clinically, as COMT rs199710929 and CYP2C9 rs28371685 were classified as benign in the ClinVar database.48,61